Alphatec (ATEC) Q4 2025 earnings review
Profitability Inflection Reached as Scale Takes Hold
Alphatec completed a defining 2025, proving it can balance hyper-growth with cash generation. Q4 revenue grew 20% year-over-year to $213 million, driven by a 23% surge in new surgeon adoption. More importantly, the company successfully transitioned its bottom line: Adjusted EBITDA margin expanded 390 basis points to 16%, and the company posted its third consecutive quarter of positive Free Cash Flow ($8 million). The heavy foundational investments of the past three years are finally yielding significant operating leverage. With 2026 guidance calling for $890 million in revenue and $134 million in Adjusted EBITDA, the trajectory is stable and highly visible, moving the narrative from cash-burn concerns to structural margin expansion.
🐂 Bull Case
Alphatec achieved positive Free Cash Flow for the full year 2025 ($3 million), completely reversing its historical cash burn. With $161M in cash and guidance for at least $20M in FCF for 2026, liquidity concerns are off the table.
Surgical revenue grew 21% in Q4, fueled by a 23% increase in net new surgeon users. The strategy of selling full procedural solutions rather than individual implants is driving compounding 'same-store' sales and stripping market share from legacy competitors.
🐻 Bear Case
Despite glowing Non-GAAP metrics, Q4 GAAP net loss was still substantial at $22 million, largely weighed down by $19.4 million in stock-based compensation and significant non-cash interest expense. Real earnings quality remains clouded by aggressive equity issuance.
Every dollar of surgical revenue growth requires roughly $0.75 in inventory and instrument CapEx. Even as EBITDA scales rapidly to $134M next year, actual Free Cash Flow will be constrained to just $20M due to these structural capital requirements.
⚖️ Verdict: 🟢
Bullish. The company is executing flawlessly against its long-term plan. The inflection to positive cash flow and Non-GAAP net income removes the primary bear thesis (need for dilutive financing), allowing investors to focus entirely on Alphatec's ~6x market-rate growth.
Key Themes
Operating Leverage is Accelerating
The massive SG&A infrastructure built between 2021 and 2023 is finally acting as a springboard rather than an anchor. Non-GAAP operating expenses in Q4 were $132 million, meaning the company captured significant leverage on its $213 million revenue base. This drove Adjusted EBITDA to a record $33 million (16% margin), a dramatic acceleration from the 11.7% margin seen a year ago.
Valence Clearance and Launch
Alphatec officially cleared and released the Valence intraoperative platform. This navigation and robotics system is fundamentally designed to democratize complex procedures like PTP (Prone Transpsoas) for a wider surgeon base. By integrating seamlessly with the EOS Insight platform, Valence transitions the company from a hardware vendor to a comprehensive surgical ecosystem provider.
Surgeon Adoption Trajectory
The engine of Alphatec's growth is expanding its user base. Net new surgeon users increased 23% in Q4 (and 20% for the full year), maintaining a stable, high-growth trajectory. This adoption metric is the most critical leading indicator for future surgical volume, proving that the clinical distinction of their procedural approach (lateral, cervical, deformity) continues to win over surgeons from legacy platforms.
Massive Stock-Based Compensation Dilutes Quality
While Adjusted EBITDA looks fantastic, the gap between GAAP and Non-GAAP results is stark. Q4 Non-GAAP Net Income was $9 million, but GAAP Net Loss was $22 million. The primary culprit is stock-based compensation, which hit $19.4 million in Q4 (9.1% of revenue) and $73.7 million for the full year. This is a real cost to shareholders that management excludes from its headline profitability metrics.
Macro Risk: Supply Chain and Tariffs
Management had previously warned of 'low single-digit millions' in tariff impacts during the second half of 2025, specifically tied to EOS units and parts imported from France. While GAAP gross margins held entirely stable at 70% in Q4, any escalation in trade tensions could pressure the COGS line for the fast-growing EOS imaging segment into 2026.
Other KPIs
Reversing. The company officially crossed into positive territory for the full year, a massive milestone. Q4 contributed $8 million, building on the $5 million generated in both Q2 and Q3, fully offsetting the seasonal $15 million burn in Q1. This removes the overhang of potential equity raises to fund operations.
Accelerating. An inflection from a $2.4 million loss in the prior year period. EPS on a Non-GAAP basis was $0.06 for the quarter. While GAAP losses remain, the positive Non-GAAP net income proves the core business model can generate true bottom-line leverage when excluding non-cash charges.
Stable. Grew 21% YoY, consistent with the >20% growth rates seen throughout 2025. This segment makes up nearly 90% of total revenue and validates the company's core focus on complex spine procedures.
Guidance
Decelerating slightly. The guidance implies 17% YoY growth, a step down from the 25% growth achieved in 2025. However, on an absolute dollar basis, the ~$126 million expected increase is massive and shows the law of large numbers taking effect rather than fundamental weakness.
Accelerating. Management explicitly raised this from a prior internal expectation of $130 million, signaling extreme confidence in operating leverage. The target implies a 15% margin for the full year, a massive 300 basis point expansion over the 12% achieved in FY25.
Accelerating. Expected to step up meaningfully from the $3 million generated in 2025. While $20M FCF on $134M of EBITDA underscores the extreme capital intensity (inventory and instruments) required to fuel 17% top-line growth, the fact that it is self-funded is a major victory.
Key Questions
Capital Intensity Scaling
You have previously noted a ratio of $0.75 in CapEx (inventory/instruments) for every $1 of surgical revenue growth. As revenue growth shifts from percentages to massive absolute dollar figures (+$120M expected in 2026), does this capital intensity ratio begin to improve due to instrument turns, or is it a permanent structural feature?
Valence Commercial Strategy
With Valence now cleared and released, how are you structuring the commercial rollout? Will you utilize a dedicated capital sales force, or rely on the existing procedural reps? And how does Valence placement directly link to expected 'convoyed sales' per procedure?
Path to GAAP Profitability
Non-GAAP operating leverage is exceptional, but GAAP net losses are still heavily impacted by stock-based compensation, which approached $74 million in FY25. As the company scales toward $1 billion in revenue, what is the timeline and strategy to bring GAAP net income into positive territory?